ArticleInternational journal of epidemiology2017
Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.
Article in International journal of epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.Renal failure · 2025Pooled it
- Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.International journal of molecular sciences · 2025Pooled it
- Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization.Lipids in health and disease · 2024Pooled it
- The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Briefings in bioinformatics · 2024Pooled it
- Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study.European journal of epidemiology · 2023Pooled it
- Hypertension, antihypertensive drugs, and age at onset of Huntington's disease.Orphanet journal of rare diseases · 2023Pooled it
- Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.American journal of human genetics · 2022Pooled it
- Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.Science translational medicine · 2020Pooled it
- Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis.PloS one · 2018Pooled it
- Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Exploring the role of inflammatory cytokines in obesity-mediated MASLD development and drug target identification.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploring the Associations and Mechanisms Between Antihypertensive Drugs and Urological Tumors: Insights from a Mendelian Randomization Study.Annals of surgical oncology · 2026Article
- Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.Research square · 2026Article
- From GWAS Signals to Molecular Mechanisms: Explainable AI for Causal Gene Prioritization and Biomolecular Target Interpretation.Biomolecules · 2026Review
- Genetically Informed Research Designs in Perinatal Pharmacoepidemiology: A Methodological Overview.Drug safety · 2026Review
- An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression.Translational psychiatry · 2026Article
- Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes.Journal of periodontal research · 2026Article
- The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study.Translational andrology and urology · 2026Article
- Cross-ancestry proteome-wide Mendelian randomization prioritizes 12 plasma protein candidates for breast cancer risk.medRxiv : the preprint server for health sciences · 2026Article
- Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.Kidney international reports · 2026Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Identification of unintended drug effects, specifically drug repurposing opportunities and adverse drug events, maximizes the benefit of a drug and protects the health of patients. However, current observational research methods are subject to several biases. These include confounding by indication, reverse causality and missing data. We propose that Mendelian randomization (MR) offers a novel approach for the prediction of unintended drug effects. In particular, we advocate the synthesis of evidence from this method and other approaches, in the spirit of triangulation, to improve causal inferences concerning drug effects. MR addresses some of the limitations associated with the existing methods in this field. Furthermore, it can be applied either before or after approval of the drug, and could therefore prevent the potentially harmful exposure of patients in clinical trials and beyond. The potential of MR as a pharmacovigilance and drug repurposing tool is yet to be realized, and could both help prevent adverse drug events and identify novel indications for existing drugs in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.